Clinical Trials
135 trialsKeyPemls-004
Peking Union Medical College Hospital
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Carisma Therapeutics Inc
A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma
Vasgene Therapeutics, Inc
KICKSTART
Effector Therapeutics
Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer
Seoul National University Hospital
PEACOCC
University College, London
NeoPACT
University of Kansas Medical Center
Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.
SL VAXiGEN
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin Melanoma
R-Pharm
Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive
Samsung Medical Center
Pemb-HT
University Health Network, Toronto
MK-3475-E90
Wellmarker Bio
Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms
R-Pharm
Pembrolizumab Plus Radiotherapy for Advanced Renal Cancer
Nanfang Hospital, Southern Medical University
Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer
Kuwait Cancer Control Center
Longitudinal Immune-phenotyping of HCC Following MK-3475
National Cancer Centre, Singapore
PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma
Provectus Pharmaceuticals
FIH
BJ Bioscience, Inc.
Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma
Keio University
Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients
Fudan University
Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma
Biocad
Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy
Zhejiang Cancer Hospital
Phase 1 First-in-human Study of JS014
Anwita Biosciences
Neo Trio
Melanoma Institute Australia
PE-PE
Consorzio Oncotech
PLIMATH
Peter MacCallum Cancer Centre, Australia
LUCACRIMUNO
Lithuanian University of Health Sciences
POCHI
Federation Francophone de Cancerologie Digestive
Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies
Biocad
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
Kineta Inc.
RBN-2397 in Combination With Pembrolizumab in Patients With SCCL
Ribon Therapeutics, Inc.
Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Northwestern University
PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma
Northwestern University
Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC
OncoSec Medical Incorporated
Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer
Valley Health System
PRINCESS
Fondazione del Piemonte per l'Oncologia
Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001)
Tianjin Medical University Cancer Institute and Hospital
KEYPAD
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Keynote-695
OncoSec Medical Incorporated
MITO28MaNGOov4
National Cancer Institute, Naples
Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901
National Hospital Organization Nagoya Medical Center
MiST
University of Leicester
Apollo
Leiden University Medical Center
Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements
National University Hospital, Singapore
Pembro-SRT
University Hospital Freiburg
PEMBROLA
Grupo Espanol Multidisciplinario del Cancer Digestivo
Pembrolizumab Plus Y90 Radioembolization in HCC Subjects
Hoosier Cancer Research Network
Neoadjuvant Chemoimmunotherapy in Recurrent Glioblastoma
University of Louisville
A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences